drugset / Trial / NCT02368301
Expanded Access Treatment Protocol CA204-143
Summary
The objective of this expanded access program is to provide treatment with elotuzumab in combination with lenalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma at U.S. sites where licensed physicians determine clinical need.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | — | — |
| Subject | Elotuzumab | Monoclonal antibody | — | — |
| Subject | Lenalidomide | Other / unclassified | — | — |